IDEA - International Dialogue for the Evaluation of Allergens

Meeting of the IDEA Working Group on the feasibility of a study to assess the effectiveness of QRA

06 April 2016

Over 2015, IDEA worked on the development of a revised QRA methodology (QRA2), focusing on total exposure of consumers to individual fragrances. For this purpose, a joint academia/industry IDEA working group has reviewed the uncertainties where a safety assessment factor (SAF) is warranted and the scientific basis for the assignment of each SAF value. Moreover, an aggregate exposure model based on actual consumer use of products which involves the utilization of these SAF values has been developed.

The work that resulted out of this science-based multi-stakeholder dialogue was presented at the IDEA Annual Review 2015 by Prof. Jim Bridges, Chair of the IDEA Supervisory Group, pointing out that the need was identified to now move on the implementation of the revised QRA and evaluate the feasibility to assess the effectiveness via monitoring of clinical data.

A working group met on April 6th, 2016 in Leuven (Belgium) to define the objectives and to initiate the discussion on the protocol of such study.

Click here to download the documentation of the meeting:

- Agenda

- Final minutes

- Key conclusions

- Presentations:

IDEA Feasability of a study to assess the effectiveness of the QRA - J. Duus-Johansen - Presentation not available

Selection of the Population Group to Study - K.-H. Jöckel (Institut für Medizinische Informatik, Biometrie und Epidemiologie, Universitätsklinikum Essen)

Fragrance Considerations on Feasibility - Graham Ellis (Head of Toxicology, Givaudan Fragrances)

Selection of clinics and testing protocols - Wolfgang Uter (Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-University Erlangen/Nurnberg, 91052 Erlangen, Germany)